FDA Expands Enhertu Approval to HER2-Ultralow Breast Cancer

(MEDPAGE today)-The Food and Drug Administration (FDA) has expanded the approval of T-DXD, TEXERTU) to include the treatment of non-discovered hormone receptors (HR)-positive, Her2-LOW/Ultralown. Approval provides for use in patients with …